​

GT Biopharma (GTBP) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

GTBP Stock Rating

GT Biopharma stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

GTBP Price Target Upside V Benchmarks

TypeNameUpside
StockGT Biopharma-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.82$2.82$2.82
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 251----1
May, 251----1
Apr, 251----1
Mar, 251----1
Feb, 251----1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 04, 2023EF HuttonHoldinitialise
Sep 13, 2022H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-30 $-24 $-18 $-12 $-6 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-5.64$-6.94---
Avg Forecast$-0.30$-6.79$-2.11$-27.30$-23.10
High Forecast$-0.30$-6.79$-2.11$-27.30$-23.10
Low Forecast$-0.30$-6.79$-2.11$-27.30$-23.10
Surprise %1780.00%2.21%---

Revenue Forecast

$5M $18M $31M $44M $57M $70M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-----
Avg Forecast-$13.00M$13.50M$9.70M$67.70M
High Forecast-$13.00M$13.50M$9.70M$67.70M
Low Forecast-$13.00M$13.50M$9.70M$67.70M
Surprise %-----

Net Income Forecast

$-40M $-32M $-24M $-16M $-8M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-7.60M$-13.16M---
Avg Forecast$-404.31K$-9.15M$-2.84M$-36.79M$-31.13M
High Forecast$-404.31K$-9.15M$-2.84M$-36.79M$-31.13M
Low Forecast$-404.31K$-9.15M$-2.84M$-36.79M$-31.13M
Surprise %1778.99%43.83%---

GTBP Forecast FAQ

Is GT Biopharma stock a buy?

GT Biopharma stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that GT Biopharma is a favorable investment for most analysts.

What is GT Biopharma's price target?

GT Biopharma's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $2.82.

How does GT Biopharma stock forecast compare to its benchmarks?

GT Biopharma's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for GT Biopharma over the past three months?

  • June 2025: 100.00% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 100.00% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 100.00% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is GT Biopharma’s EPS forecast?

GT Biopharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.11, marking a -69.60% decrease from the reported $-6.94 in 2024. Estimates for the following years are $-27.3 in 2026, and $-23.1 in 2027.

What is GT Biopharma’s revenue forecast?

GT Biopharma's average annual revenue forecast for its fiscal year ending in December 2025 is $13.5M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $9.7M, and $67.7M for 2027.

What is GT Biopharma’s net income forecast?

GT Biopharma's net income forecast for the fiscal year ending in December 2025 stands at $-2.844M, representing a -78.39% decrease from the reported $-13.162M in 2024. Projections indicate $-36.793M in 2026, and $-31.132M in 2027.